Tag Archive for: financing

Lu 177-dotatate (pink and orange) binds to somatostatin receptors (green) on neuroendocrine tumor cells (blue) and kills the cells through the release of radioactive  particles.@ NCI. Credit: Adapted from Frontiers in Oncology. January 2019. Front. Oncol. doi: 10.3389/fonc.201800663

ITM Isotope Technologies Munich SE has raised €188m ito boost radiopharma pipeline, contract manufacturing cpacity, and launch ITM-11.

© ScouserUK - pixabay.com

London-based AI-driven antibody drug discovery specialist LabGenius Ltd has closed a £35m Series B financing round.

Cellugy A/S

Danish industrial biotechnology startup Cellugy raises €4,9m with the ambition to replace petrochemicals in personal care products.

© Mikael Häggström, M.D - wikipeedia.org

Swiss antibody specialist Memo Therapeutics AG has added CHF20m to  its Series C financing, bringing the total amount raised in the funding round to CHF 45 million.

LG Draft "ball". © Locate Bio Ltd

University Nottingham spin out Locate Bio Ltd has added £9.2m venture financing led by Mercia Ventures and Business Growth Fund to its £16.2m raised before.

Structuren of Pub domain of RNF31. © RCBS protein data base

Oss-based oncology company Flindr Therapeutics BV has secured €20m  to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.

Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the  European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).

Antibodies get a second life with the right attachment (payload) (©Genmab A/S, Valby)

Genmab announced today that it will acquire privately held biotech company ProfoundBio for $1.8bn in cash. The deal is designed to help the Danish pharmaceutical company deepen its cancer pipeline with next-generation antibody-drug conjugate therapies where the company has already an inlicensing deal with former Synaffix´s ADC technology platform (which was acquired mid of 2023 by Lonza).

Double invest by Forbion in quite different topics: in-vivo celltherapy and neurological disorders. (courtesey Capstan Inc.; Engrail Thx)

Forbion, the European life sciences venture capital firm from The Netherlands, announced its participation in oversubscribed Series B financing in Capstan Therapeutics Inc. and Engrail Therapeutics. Both companies are located in San Diego, USA.

Primary astrocyte cells. © Dr Eva Latorre, Harries lab/Senisca Ltd

Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.